Risk prediction with serial myeloperoxidase monitoring in patients with acute chest pain

Clinical Chemistry

Volumn 57, Issue 12, 2011, Pages 1762-1770

  Nicholls, Stephen J ^a   Wilson Tang, W H ^a   Brennan, Danielle ^a   Brennan, Marie Luise ^a   Mann, Shirley ^a   Nissen, Steven E ^a   Hazen, Stanley L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYELOPEROXIDASE; TROPONIN I;

ACCURACY; ACUTE CHEST PAIN; ADULT; ARTICLE; BIOASSAY; CARDIOVASCULAR RISK; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HEART DISEASE; HUMAN; MAJOR ADVERSE CARDIAC EVENT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT MONITORING; PREDICTION; RISK ASSESSMENT; SERIAL MONITORING; THORAX PAIN;

ACUTE CORONARY SYNDROME; AGED; ANGINA, UNSTABLE; BIOLOGICAL MARKERS; CHEST PAIN; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEROXIDASE; REFERENCE VALUES; RISK ASSESSMENT; ROC CURVE; TROPONIN I;

EID: 82755195303     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2011.166827     Document Type: Article

References (39)

1. Tang WH, Wu Y, Nicholls SJ, Brennan DM, Pepoy M, Mann S, et al. Subclinical myocardial necrosis and cardiovascular risk in stable patients undergoing elective cardiac evaluation. Arterioscler Thromb Vasc Biol 2010;30:634-40.
2. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26.
3. Ridker PM. Clinical applications of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9. (Pubitemid 36158034)
4. Pepys MB, Hawkins PN, Kahan MC, Tennent GA, Gallimore JR, Graham D, et al. Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res 2005;97:e97-103.
5. Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF, et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009;302:37-48.
6. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005;25:1102-11. (Pubitemid 40776595)
7. Abu-Soud HM, Hazen SL. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem 2000;275:37524-32. (Pubitemid 32004861)
8. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A, et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science (Wash DC) 2002;296:2391-4. (Pubitemid 34734213)
9. Hazen SL, Zhang R, Shen Z, Wu W, Podrez EA, MacPherson JC, et al. Formation of nitric oxide-derived oxidants by myeloperoxidase in monocytes: pathways for monocyte-mediated protein nitration and lipid peroxidation in vivo. Circ Res 1999;85:950-8. (Pubitemid 29534170)
10. Fu X, Kassim SY, Parks WC, Heinecke JW. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7): a mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 2001;276:41279-87.
11. Sugiyama S, Kugiyama K, Aikawa M, Nakamura S, Ogawa H, Libby P. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol 2004;24:1309-14. (Pubitemid 38880026)
12. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004;114:529-41. (Pubitemid 39572103)
13. Bergt C, Pennathur S, Fu X, Byun J, O'Brien K, McDonald TO, et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A 2004;101:13032-7. (Pubitemid 39167578)
14. Undurti A, Huang Y, Lupica JA, Smith JD, DiDonato JA, Hazen SL. Modification of high density lipoprotein by myeloperoxidase generates a proinflammatory particle. J Biol Chem 2009;284:30825-35.
15. Kutter D, Devaquet P, Vanderstocken G, Paulus JM, Marchal V, Gothot A. Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit ? Acta Haematol 2000;104:10-5.
16. Nikpoor B, Turecki G, Fournier C, Theroux P, Rouleau GA. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J 2001;142:336-9. (Pubitemid 32706293)
17. Pecoits-Filho R, Stenvinkel P, Marchlewska A, Heimburger O, Barany P, Hoff CM, et al. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl 2003:S172-6. (Pubitemid 36513403)
18. Asselbergs FW, Tervaert JW, Tio RA. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2004;350:516-8; author reply 8.
19. Asselbergs FW, Reynolds WF, Cohen-Tervaert JW, Jessurun GA, Tio RA. Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. Am J Med 2004;116:429-30. (Pubitemid 38299491)
20. Rudolph V, Rudolph TK, Kubala L, Clauberg N, Maas R, Pekarova M, et al. A myeloperoxidase promoter polymorphism is independently associated with mortality in patients with impaired left ventricular function. Free Radic Biol Med 2009;47:1584-90.
21. Castellani LW, Chang JJ, Wang X, Lusis AJ, Reynolds WF. Transgenic mice express human MPO -463G/A alleles at atherosclerotic lesions, developing hyperlipidemia and obesity in -463G males. J Lipid Res 2006;47:1366-77. (Pubitemid 44079890)
22. McMillen TS, Heinecke JW, LeBoeuf RC. Expression of human myeloperoxidase by macrophages promotes atherosclerosis in mice. Circulation 2005;111:2798-804. (Pubitemid 40791552)
23. Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Horkko S, Barnard J, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007.
24. Meuwese MC, Stroes ES, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007;50:159-65. (Pubitemid 47002189)
25. Ndrepepa G, Braun S, Mehilli J, von Beckerath N, Schomig A, Kastrati A. Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. Eur J Clin Invest 2008;38:90-6. (Pubitemid 351143413)
26. Wong ND, Gransar H, Narula J, Shaw L, Moon JH, Miranda-Peats R, et al. Myeloperoxidase, subclinical atherosclerosis, and cardiovascular disease events. JACC Cardiovasc Imaging 2009;2:1093-9.
27. Cavusoglu E, Ruwende C, Eng C, Chopra V, Yanamadala S, Clark LT, et al. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol 2007;99:1364-8. (Pubitemid 46686633)
28. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003;108:1440-5. (Pubitemid 37176448)
29. Morrow DA, Sabatine MS, Brennan ML, de Lemos JA, Murphy SA, Ruff CT, et al. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 2008;29:1096-102. (Pubitemid 351844877)
30. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003;349:1595-604. (Pubitemid 37288567)
31. Vita JA, Brennan ML, Gokce N, Mann SA, Goormastic M, Shishehbor MH, et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 2004;110:1134-9. (Pubitemid 39319014)
32. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA 1982;247:2543-6. (Pubitemid 12155954)
33. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27:157-72, 2008; discussion 207-12.
34. Apple FS, Smith SW, Pearce LA, Schulz KM, Ler R, Murakami MM. Myeloperoxidase improves risk stratification in patients with ischemia and normal cardiac troponin I concentrations. Clin Chem 2011;57:603-8.
35. Goldmann BU, Rudolph V, Rudolph TK, Holle AK, Hillebrandt M, Meinertz T, Baldus S. Neutrophil activation precedes myocardial injury in patients with acute myocardial infarction. Free Radic Biol Med 2009;47:79-83.
36. Eggers KM, Dellborg M, Johnston N, Oldgren J, Swahn E, Venge P, Lindahl B. Myeloperoxidase is not useful for the early assessment of patients with chest pain. Clin Biochem 2010;43:240-5.
37. Borges FK, Stella SF, Souza JF, Wendland AE, Werres Junior LC, Ribeiro JP, Polanczyk CA. Serial analyses of C-reactive protein and myeloperoxidase in acute coronary syndrome. Clin Cardiol 2009;32:E58-62.
38. McCann CJ, Glover BM, Menown IB, Moore MJ, McEneny J, Owens CG, et al. Prognostic value of a multimarker approach for patients presenting to hospital with acute chest pain. Am J Cardiol 2009;103:22-8.
39. Klebanoff SJ. A peroxidase-mediated antimicrobial system in leukocytes. J Clin Invest 1967;46:1078-85.